MX2010001730A - Composicion antimicotica. - Google Patents

Composicion antimicotica.

Info

Publication number
MX2010001730A
MX2010001730A MX2010001730A MX2010001730A MX2010001730A MX 2010001730 A MX2010001730 A MX 2010001730A MX 2010001730 A MX2010001730 A MX 2010001730A MX 2010001730 A MX2010001730 A MX 2010001730A MX 2010001730 A MX2010001730 A MX 2010001730A
Authority
MX
Mexico
Prior art keywords
antifungally
antifungal composition
component
emulsifying
independently
Prior art date
Application number
MX2010001730A
Other languages
English (en)
Inventor
Guenter Ditzinger
Christian Bucher
Estelle Dubois
Delphine Marchaud
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of MX2010001730A publication Critical patent/MX2010001730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe una composición farmacéutica para administración oral que es auto-emulsionante al hacer contacto con una fase acuosa, en particular fluidos gastrointestinales, y la cual comprende: (a) un compuesto antimicóticamente activo de la fórmula (l) (ver fórmula l) en donde R1, R2 R3 y son independientemente uno del otro hidrógeno, F o Cl; o una sal de adición con ácidos farmacéuticamente aceptables del mismo, y (b) un vehículo que comprende un componente solubilizador para el componente antimicóticamente efectivo (a).
MX2010001730A 2007-08-21 2008-08-20 Composicion antimicotica. MX2010001730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114652 2007-08-21
PCT/EP2008/060905 WO2009024590A2 (en) 2007-08-21 2008-08-20 Antifungal composition

Publications (1)

Publication Number Publication Date
MX2010001730A true MX2010001730A (es) 2010-03-10

Family

ID=38656753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001730A MX2010001730A (es) 2007-08-21 2008-08-20 Composicion antimicotica.

Country Status (15)

Country Link
US (1) US8536208B2 (es)
EP (1) EP2192893B1 (es)
JP (1) JP5576279B2 (es)
KR (1) KR101493546B1 (es)
CN (1) CN101784259B (es)
AU (1) AU2008290536B2 (es)
BR (1) BRPI0815595B8 (es)
CA (1) CA2697328C (es)
ES (1) ES2551125T3 (es)
HK (1) HK1141742A1 (es)
MX (1) MX2010001730A (es)
PL (1) PL2192893T3 (es)
PT (1) PT2192893E (es)
WO (1) WO2009024590A2 (es)
ZA (1) ZA201000925B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011382468B2 (en) * 2011-12-02 2015-06-11 Colgate-Palmolive Company Oral care composition comprising isobutyl magnolol
AU2017283276B2 (en) * 2016-06-20 2023-02-16 Capretto Ehf. Thermostable formulation of biologically active substances
CN105943500B (zh) * 2016-07-08 2019-01-04 河南省立眼科医院 一种含有艾沙康唑的眼用纳米胶束抗真菌溶液
WO2018219804A1 (en) * 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
GB201813229D0 (en) * 2018-08-14 2018-09-26 Ocutec Ltd Formulation
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
AU2931399A (en) 1998-03-06 1999-09-20 F. Hoffmann-La Roche Ag 3-(4-(4-cyanophenyl)thiazol-2-y))-1-(1h-1,2,4-triazol-1-yl) -butan-2-ol derivatives having antifungal activity
JP2002513750A (ja) * 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
CN1185230C (zh) 1999-11-02 2005-01-19 巴斯利尔药物股份公司 N－取代的氨基甲酰氧基烷基－吡咯鎓衍生物
JP2001302544A (ja) * 1999-12-10 2001-10-31 Takeda Chem Ind Ltd 経口用医薬組成物
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
JP2007515458A (ja) * 2003-12-23 2007-06-14 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｉｖプロテアーゼ阻害剤の自己ミクロ乳化性薬剤送達システム
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
KR20070084531A (ko) * 2004-11-24 2007-08-24 머크 앤드 캄파니 인코포레이티드 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형
KR20080055956A (ko) * 2005-09-29 2008-06-19 레프로스 쎄라피우틱스 아이엔씨. 향상된 생체이용률을 가지며, 스테로이드 유도체와폴리글리콜리세드 글리세리드를 포함하는 제제
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol

Also Published As

Publication number Publication date
BRPI0815595B8 (pt) 2021-05-25
BRPI0815595A8 (pt) 2018-06-19
CA2697328A1 (en) 2009-02-26
CN101784259B (zh) 2013-03-27
AU2008290536B2 (en) 2012-02-09
JP5576279B2 (ja) 2014-08-20
KR101493546B1 (ko) 2015-02-16
PL2192893T3 (pl) 2015-12-31
ZA201000925B (en) 2010-10-27
KR20100064370A (ko) 2010-06-14
AU2008290536A1 (en) 2009-02-26
BRPI0815595A2 (pt) 2015-03-03
CN101784259A (zh) 2010-07-21
WO2009024590A2 (en) 2009-02-26
US20110281918A1 (en) 2011-11-17
EP2192893A2 (en) 2010-06-09
CA2697328C (en) 2015-08-11
ES2551125T3 (es) 2015-11-16
WO2009024590A3 (en) 2009-06-04
PT2192893E (pt) 2015-11-09
HK1141742A1 (en) 2010-11-19
EP2192893B1 (en) 2015-08-19
JP2010536826A (ja) 2010-12-02
US8536208B2 (en) 2013-09-17
BRPI0815595B1 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
TNSN08407A1 (en) Organic compounds
WO2008142055A3 (en) Antiviral agents
TW200744588A (en) Pharmaceutical composition for external use
UA94065C2 (en) Dihydropseudoerythromycin derivatives
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
GEP20125487B (en) Organic compounds and their use
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
IN2012DN02465A (es)
MY153921A (en) Aminopyrazole derivatives
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
WO2009016462A3 (en) Substituted bicyclolactam compounds
MY151295A (en) Pyrimidyl indoline compound
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2010001730A (es) Composicion antimicotica.
WO2010084115A3 (en) Antiviral agents
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
UA105229C2 (uk) Фармацевтичний склад
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.

Legal Events

Date Code Title Description
FG Grant or registration